-
81.
公开(公告)号:EP4029513A1
公开(公告)日:2022-07-20
申请号:EP21204226.1
申请日:2016-09-29
摘要: The disclosure is related to a method of treating a disorder, such as Prader Willi Syndrome (PWS), obesity or hyperphagia, in a subject using a melanocortin-4 receptor (MC4R) agonist. Also described is method of treating a subject having a deficiency in the pro-opiomelanocortin (POMC)-MC4R pathway, such as a POMC-null or a PCSK-null subject, using a MC4R agonist.
-
公开(公告)号:EP3978927A3
公开(公告)日:2022-06-22
申请号:EP22152107.3
申请日:2021-02-19
发明人: Steinhagen, Katja , Messing, Claudia , Lattwein, Erik , Stiba, Konstanze , Lindhorst, Fabian , Neugebauer, Eva , Müller, Marcel , Corman, Victor
IPC分类号: G01N33/569 , C07K14/005 , C07K14/165
摘要: The present invention relates to a method for diagnosing a SARS-CoV-2 infection comprising the step of detecting the presence or absence of an antibody to SEQ ID NO: 1, preferably IgA class antibody, in a sample from a subject, a method for the differential diagnosis of a coronavirus infection, a use of an antibody to SEQ ID NO: 1, preferably IgA class antibody for diagnosing a SARS-CoV-2 infection or for the differential diagnosis of a coronavirus infection, preferably for distinguishing between a SARS-CoV-2, MERS and NL63, 229E, OC43 and HKU1 infection, and a kit comprising a polypeptide comprising SEQ ID NO: 1 or a variant thereof, preferably coated to a diagnostically useful carrier and one or more, preferably all reagents from the group comprising an antibody to SEQ ID NO: 1, a washing buffer, a means for detecting the presence of an antibody, preferably IgA class antibody, preferably a secondary antibody binding specifically to IgA class antibodies, preferably comprising a detectable label, and a dilution buffer.
-
公开(公告)号:EP3999638A1
公开(公告)日:2022-05-25
申请号:EP20737499.2
申请日:2020-07-15
-
公开(公告)号:EP3861524A1
公开(公告)日:2021-08-11
申请号:EP19779043.9
申请日:2019-10-04
-
公开(公告)号:EP3760217A1
公开(公告)日:2021-01-06
申请号:EP19183694.9
申请日:2019-07-01
申请人: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft , Charité - Universitätsmedizin Berlin
IPC分类号: A61K38/17 , C07K14/725 , C07K14/705
摘要: The present invention is directed to the field of immunotherapy, in particular, adoptive T cell therapy or T cell receptor (TCR) gene therapy of cancer. The invention provides a nucleic acid encoding at least one TCR alpha or beta chain construct of a TCR construct capable of specifically binding to a peptide from the T-cell lineage specific antigen CD5, preferably SEQ ID NO: 1, in the context of a human MHC I such as HLA-A*02, in particular HLA-A*02:01. The invention also provides corresponding proteins and host cells, preferably, CD8+ T cells, expressing said TCR construct. Treatment optionally is in the context of allogeneic stem cell transplantation, in particular, mismatch-transplantation, or haploidentical transplantation, or in combination with an agent capable of inhibiting expression of HLA-A*02 in the TCR-transgenic T cells. The invention thus also provides compositions and kits comprising the nucleic acids of the invention in combination with an agent capable of inhibiting expression of HLA-A*02, and, as well as the medical use of such compositions and kits. The nucleic acids, compositions and kits, proteins or host cells may be for use in the diagnosis, prevention and/or treatment of a CD5-positive T-cell lymphoma or T-cell leukemia, no matter whether the antigen is expressed on the cell surface, intracytoplasmic or in both manners.
-
公开(公告)号:EP3731861A1
公开(公告)日:2020-11-04
申请号:EP19700444.3
申请日:2019-01-02
申请人: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft , Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts , Imperial College Innovations Limited , Charité - Universitätsmedizin Berlin
-
87.
公开(公告)号:EP3670530A1
公开(公告)日:2020-06-24
申请号:EP18213482.5
申请日:2018-12-18
申请人: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft , Charité - Universitätsmedizin Berlin
IPC分类号: C07K14/725 , C07K16/30
摘要: The present invention is directed to the field of immunotherapy, in particular, adoptive T cell therapy or T cell receptor (TCR) gene therapy of cancer, in particular, of B cell lymphoma or B cell leukemia. The invention provides a nucleic acid encoding at least one TCR alpha or beta chain construct of a TCR construct capable of specifically binding to a peptide of SEQ ID NO: 1, derived from the lineage specific antigen CD22, in the context of HLA-A2 and to subsequently lyse CD22-positive cells. The invention further provides a corresponding protein and host cell, e.g., a CD8+ T cell, pharmaceutical compositions comprising the same, and therapeutic use for treatment of B cell lymphoma or B cell leukemia, such as diffuse large B-cell lymphoma (DLBCL).
-
公开(公告)号:EP3633604A1
公开(公告)日:2020-04-08
申请号:EP18198717.3
申请日:2018-10-04
发明人: BRANDT, Alexander , KADAS, Ella Maria , YADAV, Sunil Kumar , MOTAMEDI, Seyedamirhosein , PAUL, Friedemann
摘要: The invention relates to a method and a computer program for automatic shape quantification of an optic nerve head from three-dimensional image data (1) acquired with optical coherence tomography, comprising the steps of:
a) Providing (100) three-dimensional image data (1) of the retina, the image data comprising at least a portion of the optic nerve head, wherein the image data comprises pixels with associated pixel values;
b) In the three-dimensional image data (1) identifying (200, 300) anatomic portions of the optic nerve head, the anatomic portions comprising a retinal pigment epithelium (RPE) portion (3) and an inner limiting membrane (ILM) portion (2);
c) Determining an RPE polygon mesh (30) for a lower boundary of the retinal pigment epithelium portion (3), wherein the RPE polygon mesh (30) extends along the lower boundary of the retinal pigment epithelium portion (3);
d) Determining an ILM polygon mesh (20) for the inner limiting membrane portion (2), wherein the ILM polygon mesh (20) extends along the inner limiting membrane portion (2);
e) Determining a morphologic parameter (10) of the optic nerve head from the RPE polygon mesh (30) and the ILM polygon mesh (20);
f) Displaying the morphologic parameter (10) of the optic nerve head and/or a representation of at least a portion of the RPE polygon mesh (30) and/or a representation of at least a portion of the ILM polygon mesh (20).-
公开(公告)号:EP3589306A1
公开(公告)日:2020-01-08
申请号:EP18706531.3
申请日:2018-02-27
-
公开(公告)号:EP3492605A1
公开(公告)日:2019-06-05
申请号:EP17204951.2
申请日:2017-12-01
IPC分类号: C12Q1/6851 , C12Q1/6876 , C12Q1/6883
摘要: The invention relates to a method of assessing a time-related physiological parameter selected from a person's circadian rhythm, a person's internal time and the robustness/strength of a person's circadian rhythm. The method comprises the steps of determining in a sample of blood monocytes obtained from said person an expression level of a plurality of circadian oscillatory genes, and assessing the time-related physiological parameter based on the determined expression level.
-
-
-
-
-
-
-
-
-